Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Filiaciones

Wei A.H.:

The Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia

Panayiotidis P.:

National and Kapodistrian University of Athens Medical School, Laiko General Hospital, Athens, Greece

Montesinos P.:

Hospital Universitario y Politécnico La Fe, Valencia, Spain and CIBERONC, Instituto Carlos III, Madrid, Spain

Laribi K.:

Centre Hospitalier–Le Mans, Le Mans, France

Novak J.:

Department of Internal Medicine and Hematology, University Hospital Královské Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic

Fiedler W.:

Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Pagoni M.:

Evaggelismos General Hospital, Athens, Greece

Bergeron J.:

CIUSSS-EMTL, Installation Maisonneuve-Rosemont, Montreal, Quebec City, Canada

Ting S.B.:

Eastern Health and Monash University, Melbourne, VIC, Australia

Hou J.-Z.:

University of Pittsburgh Medical Center (UPMC) Cancer Center, Pittsburgh, PA, United States

Anagnostopoulos A.:

George Papanicolaou General Hospital, Thessalonica, Greece

McDonald A.:

Netcare Pretoria East Hospital, Moreletapark, Pretoria, South Africa

Murthy V.:

Heartlands Hospital, Birmingham, United Kingdom

Yamauchi T.:

University of Fukui Hospital, Fukui, Japan

Wang J.:

Chinese Academy of Medical Sciences, Tianjin, China

Jiang Q.:

AbbVie Inc., North Chicago, IL, United States

Sun Y.:

AbbVie Inc., North Chicago, IL, United States

Chyla B.:

AbbVie Inc., North Chicago, IL, United States

Mendes W.:

AbbVie Inc., North Chicago, IL, United States

DiNardo C.D.:

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX